Business Context and Reporting Period
This Form 8-K Current Report was filed by CytoSorbents Corporation on July 26, 2018. The filing reports the entry into a material definitive agreement regarding the company's equity offering program.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual amendment and does not contain financial performance data.
Material Changes
On July 26, 2018, the Company entered into Amendment No. 1 to its Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. (originally dated November 4, 2015). This amendment extends the term of the Sales Agreement until the first to occur of:
- The termination of the Sales Agreement by Cantor or the Company, as permitted therein.
- The expiration of the Company's registration statement on Form S-3 filed with the SEC on July 26, 2018.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No specific risks or contingencies are detailed beyond the standard terms of the amended sales agreement.
Investor Verification Checklist
- Verify the status and expiration date of the Form S-3 registration statement filed on July 26, 2018.
- Review the full text of Amendment No. 1 to the Sales Agreement (Exhibit 10.1) for specific termination rights and conditions.
- Confirm the current outstanding share count and any recent sales under the existing Sales Agreement prior to this amendment.